Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development
Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 3,831,727 | $481,226,574 | +841% | 0.94% |
| 2. | D E Shaw D. E. Shaw | 1,366,207 | $171,581,937 | -14% | 0.12% |
| 3. | AQR Capital Management Cliff Asness | 1,364,805 | $171,405,897 | -1% | 0.14% |
| 4. | Renaissance Technologies Jim Simons | 1,045,106 | $131,254,863 | +30% | 0.17% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 831,905 | $104,478,949 | +6% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | $8,787,120.00 | 643,000 | 2019-05-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $135.00 | 2,223 | $300,105.00 | 6,330 | 2025-07-08 | Filing | |
| $126.25 | 3,806 | $480,507.50 | 5,427 | 2025-05-19 | Filing | |
| $150.02 | 8,760 | $1,314,141.91 | 11,318 | 2025-03-07 | Filing | |
| $157.21 | 110 | $17,293.10 | 5,426 | 2024-12-09 | Filing | |
| $204.22 | 431 | $88,018.82 | 5,316 | 2024-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,290,651 | $2,171,532,858 | 0.04% | |
| 2. | 15,802,122 | $1,984,588,503 | 1.57% | |
| 3. | 13,555,466 | $1,702,431,056 | 0.03% | |
| 4. | 7,468,807 | $938,007,471 | 0.04% | |
| 5. | 4,798,420 | $602,633,568 | 0.11% |
News See All
Top 10 Medical AI Companies to Buy According to Analysts
Artificial intelligence is transforming medical sciences in ways not seen before.
Biogen Inc. (BIIB): A Bull Case Theory
We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize the bulls’ thesis on BIIB.
BofA Lowers PT on Biogen (BIIB) to $142 From $143, Keeps a Neutral Rating
Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on Biogen Inc.
11 Cheap Pharmaceutical Stocks to Buy Now
The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...
Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Call Transcript
Operator: Good morning. My name is Cynthia and I will be your conference operator today.
Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push
Biogen Inc. (NASDAQ:BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc.
10 Most Undervalued Pharma Stocks to Buy Now
Pharmaceutical manufacturing in the U.S. has declined sharply over recent decades, with most active ingredient production shifting overseas due to lower labor costs. In 2023, the U.S.
Billionaire Hedge Funds
